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Summary   
The clinical utility of molecular diagnostic approaches in allergy investigation is 
increasingly being recognized to play a significant role in the management of 
allergic patients. Determining the sensitisation pattern, which is best achieved 
through the use of component resolved diagnostics (CRD), allows effective risk 
stratification, appropriate treatment and patient selection for immunotherapy.  
In order to assess the diagnostic service provisions for in vitro allergy testing 
across Europe, a survey was carried out via the total IgE and Specific IgE external 
quality assurance schemes run by UK NEQAS Immunology, Immunochemistry & 
Allergy.  
This survey assessed allergy testing and in particular allergen-components 
offered by the laboratories and found a wide variability in service provision, 
particularly between the UK and EU. Furthermore, there was lack of 
standardisation for acquisition of clinical information to aid allergen (and 
component) selection, gating strategy, testing algorithms and clinical 
interpretation. Interestingly, a significant proportion of laboratories (the 
majority from EU) stated that they used the results for peanut components for 
risk stratification. However, vast majority of participants were unaware of 
guidelines relating to the use of allergen component testing and agreed further 
education would assist in reaching a common platform.      
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Hence, this survey has highlighted that although CRD has been adopted into 
routine diagnostics across Europe; it is potentially compromised by lack of 
standardised protocols and guidance sources. Consequently, there is a need for 
local or national standards and education through External Quality Assurance 
services on the performance and application of CRD into allergy investigation.  
Max Word count = 250 (above summary 248) 
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Introduction 
Recent developments in molecular techniques have given rise to advances in 
the knowledge of properties of specific allergens, and has aided their clinical 
utility in both diagnosis and management of allergic patients. These advances 
have allowed for the use of specific allergen components in in vitro diagnosis in 
what is termed Molecular diagnosis, or Component Resolved Diagnosis (i.e. 
identifying specific IgE to distinct allergenic sub-components of the whole 
allergen extract). Component Resolved Diagnosis (CRD) provides clinicians with 
an extended diagnostic toolkit with potential for cross-sensitisation profiling, 
risk stratification, and allergen identification for improved patient 
management [1, 2]. Benefits to the patient may include negating the need to 
undergo the risk of an  Oral Food Challenge where sensitisation to high-risk 
components is present, or  eliminating the requirement for dietary exclusions 
where cross-reactive components associated with low risk of systemic 
reactions are identified [3]. These potential patient benefits are important 
when considering patient health, quality of life, and the risks and costs 
associated with challenge tests.  
There is worldwide data suggesting that the prevalence of allergy is increasing. 
A recent systematic review of food allergy across Europe assessed prevalence 
of food allergy in both adults and children [4].  A pooled lifetime prevalence of 
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self-reported allergy was found to be 17.3%, with point prevalence of 5.9%. 
Sensitisation to more than one food, as indicated by specific IgE, was found in 
10.1%. However the prevalence of true allergy, as confirmed by food challenge 
(either open or double blind placebo controlled), was much lower at 0.89% in 
children and 0.99% in adults (overall point prevalence of 0.93%). This distinct 
discrepancy between self-reporting, in vitro sensitisation assessment and 
confirmed food allergy illustrates the need for a greater use of more accurate 
diagnostic testing to diagnose or exclude allergy. The difference in prevalence 
between self-reported allergy and clinically confirmed allergy was reflected 
across Europe [4, 5], with the greatest difference seen in Northern Europe 
(14.51% self-reported; 1.12% confirmed point prevalence). Unfortunately, 
clinical false-positivity, the prevalence of detectable but irrelevant sensitisation 
to whole allergen extracts which does not lead to clinical symptoms is often 
much higher than true clinical allergy for many allergens.  
When assessing and reporting allergy; the distinction between asymptomatic 
sensitisation, irrelevant in-vitro cross-reactivity and a clinically symptomatic 
allergy is vital. CRD have been found to have a useful role in distinguishing 
allergy due to primary allergen sensitisation from benign cross-sensitisation 
due to structural similarities between allergens, but which results in positive 
testing. Panels of CRD allergens have shown to be of clinical value in 
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prevalence studies, and sensitisation patterns can sometimes indicate likely 
severity of symptoms (e.g. Ara h 2 as a risk factor for positive challenge testing) 
or mostly benign cross sensitisation (e.g. Cross reactive carbohydrate 
determinants or labile PR10 proteins). Peach and apple are known to be 
frequent sensitisers in Europe [6]. Sensitisation LTPSs (Lipid Trasfer proteins) 
such as apple Mal d 3 and Peach Pru p 3 are linked to clinical reactions [3].   
The European prevalence of peanut sensitisation may be as high as 2.7% [5] 
but only 1/5 of these may have clinically significant allergic symptoms. In a 
study of childhood peanut allergy, 22.4% of sensitised 8 year olds (of 933 
participants) had confirmed peanut allergy by double blind placebo controlled 
food challenge [7]. Comparison of sensitisation rates to individual components 
determined the peanut component Ara h 2 to be the best predictor of clinical 
outcome. The clinical utility of Ara h 2 was also shown by a prospective study 
comparing specific IgE to peanut Ara h 2 and outcome of food challenge [8]. 
Ara h 2 and Cor a 14 were better discriminators of allergy from tolerance than 
whole peanut or hazelnut extract respectively. In a separate study, Ara h 2 sIgE 
had the best correlation with challenge outcome, superior to Ara h 1, 3, 8, 9 
and peanut specific IgE [9].  The close association of an immunodominant 
major component sensitisation (often referred to a species specific 
sensitisation) to probability of clinical allergy is to be expected; components 
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are usually named in order of discovery or because they are ranked in order of 
frequency of sensitisation in a population  and this mirrors the order of  
immunodominant allergens in a response. When cross reactive sensitisation is 
present this obscures the presence or absence of species-specific sensitisation, 
thus identifying or eliminating signal from cross-reactive components is a key 
feature in component assay performance. Thus Ara h 1, 2, 3 and 6 are also 
species-specific allergen components associated with clinical peanut allergy, 
but Ara H2 is most strongly associated and the best predictor in isolation. 
Conversely, sensitisation to the cross-reactive PR10 protein Ara h 8 alone is 
often a marker of false positivity due to pollen sensitisation and associated 
with minor reactions predominantly. 
The use of component testing is increasingly used  in the clinical management 
of patients reducing the need for risky food challenges for confirmation of 
allergy, allowing effective risk-assessment of patients without challenge, and 
accurately identifies sensitising allergens for appropriate management 
including patient selection for immunotherapy. It may be helpful that 
laboratories supporting allergy clinics provide these services as part of their 
testing repertoire. In order to assess service provision, UK NEQAS Immunology, 
Immunochemistry & Allergy (IIA, Sheffield, UK) conducted a survey of 
participants. 
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Methods 
Allergen component testing survey was distributed via UK NEQAS IIA as part of 
the total IgE scheme (n=248) and specific IgE scheme (n=383) to the participating 
laboratories offering allergy diagnostic testing to ascertain the breadth of allergy 
services and local practices including allergen component testing.  
The survey contained 25 questions; eight questions focused on the geographical 
location of the participating laboratory, its workload, requesting pattern and the 
basic diagnostic allergy services provided, whilst the remaining seventeen 
focused particularly on the use of allergen component testing.  
The responses from this survey were collated in a spreadsheet for analysis.  
 
Results 
Overall 19% (n=73) of all participants in the specific IgE scheme surveyed 
(n=383), provided responses. However, not all answered every question and 
therefore the response rate is quoted for each.  
Location, allergy workload and requesting sources 
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In terms of the geographical location, over half (n=41, 56%) of the responding 
laboratories were located in the European Union (EU) whilst 26% (n=19) were 
from the UK and a smaller number (n=13, 18%) were outside the EU.  
In 2013 and 2014, it appears that on average 40% of respondents  performed up 
to 10,000 allergy tests per annum. Roughly 20% of responding laboratories 
performed between 20,000 to 30,000 tests (Table 1). Interestingly, a small 
number of laboratories (n=15 in 2013 and 21 in 2014) performed the highest 
number of tests; between 30,000 and 100,000+ tests per annum (Table 1).  
There was a wide variation in the number of allergy test requests coming from 
both primary and secondary care settings. Of 73 respondents, 32% (n=23) 
stated that up to 20% were from a source other than primary or secondary 
care (Table 2).  This may reflect private allergy testing provided in some areas.  
Receipt and processing of allergy requests  
More than half of the respondents (55% n=35 out of 64 total) vetted allergy 
requests on receipt for appropriateness. The majority of these were EU (n=17) 
laboratories followed by the UK (n=10).  
Interestingly, most services do not require a completed allergy questionnaire 
proforma to provide clinical information for interpretation and allergen 
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selection: the majority 95% (n=62) of total 65 respondents answered no; whilst 
only 5% (n=3) did so, (2 from UK and 1 EU laboratory).   
Out of 67 respondents, the majority (65% n=44) performed allergy tests on all 
allergens requested, whilst 35% (n=23) did not. These may be due to processing 
issues e.g. insufficient sample received, or vetting protocol upon allergy request 
receipt to modify requests to ensure relevant testing.  
In total, 23% (15/64 respondents) used both allergen mixtures and panels whilst 
a higher proportion, 45% (29/64 respondents), used allergen mixtures only.  
Phadiatop methodology was used by 9% (n=6) of the responding 64 laboratories.   
 
Allergen component testing  
Availability 
Allergen component testing was routinely offered by 78% (n=45) of the 58 
respondents. This included 26 EU, 11 UK, and 8 Non-EU laboratories.  
Access to Primary care 
Furthermore, a significant proportion (74% n=41) of the responding 56 
laboratories (mainly located in EU n=25), permitted allergen component 
requests from GPs and/or primary care health professionals. 
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Gating policy 
Interestingly, 35% (n=19/54 respondents) stated that component testing is 
only performed if the allergen screen was positive. Therefore, the majority 
(65% n=35) appear to perform the testing regardless of the allergen screen 
outcome. There were roughly an equal proportion of laboratories stating that 
component testing was allergen dependent (yes, 53% n=26) and allergen 
independent (no, 47% n=24).   
Test selection policy 
When asked if there was a testing algorithm for allergy and / or allergen 
components testing, a significant proportion of the 55 respondents did not 
have any algorithm for allergy (n=34, 63%) or for the components (n=38, 67%). 
However, a small group (n=21 and n=18 respectively) of laboratories stated 
they had algorithms for allergy and component testing respectively. These 
were mainly located in EU countries outside the UK (n=10/9 respectively) 
figure 1.  
Methodology 
The predominant method used for allergen component testing was 
unsurprisingly that of the largest test provider (Phadia ImmunoCAP) for 82% (n= 
42) of 51 respondents. Hence the measuring units were reported in the majority 
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as KU/L (n=20) and KUA/L (n=18). Four laboratories used the semi-quantitative 
ISAC (Immuno Solid-phase Allergen Chip) alone. Two laboratories stated that 
they perform both single component and ISAC testing.  
Cut-off levels 
The vast majority of the 45 responding laboratories reported the cut-off range 
ĨŽƌĂůůĞƌŐĞŶĐŽŵƉŽŶĞŶƚƐƚŽďĞч ? ? ? ?KUA/L (47% n=21) followed by ч ? ? ?KUA/L 
(33% n=15) whilst a small proportion reported other variations of uncertain 
provenance such as 0.3ISU-E, 1.5 AU/mL, >0.35 or even <0.01KUA/L. The survey 
did not explore if any such alterative were locally validated according to ISO 
requirements. 
Samples 
All 47 respondents (100%) stated serum as the preferred matrix including two 
EU laboratories that accept both serum and plasma. Of the 42 respondents, 57% 
(n=24) stated the minimum volume for testing to be 0.3ml, followed by 0.5ml in 
33% (n=14) and 1.0ml in 10% (n=4) of the responding laboratories.  
Repertoire 
All laboratories were asked if they offered testing for 17 common allergens. The 
results are summarised in figure 2.   Approximately two thirds of the 
respondents provided either yes/no response.  The majority offer components 
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for: a) peanut [n=46], b) egg [n=42], c) venoms [n=37], followed by nuts [n=36] 
and Omega-5-gliadin [n=36]. On average, more laboratories do provide 
components for all of the listed allergen categories except one (meat alpha-gal) 
as illustrated in figure 2.   
 
 
Use of recombinants in peanut allergic patients 
Routine diagnosis 
47 laboratories responded to whether they routinely performed allergen 
component testing for peanut positive patients. Only 38% (n=18) answered yes 
including 12 EU laboratories, while the remaining 62% (n=29) answered no.  
Risk stratification 
Interestingly, a significant proportion, 74% (n=34) of 46 respondents stated that 
they used the results for peanut components to stratify clinical risk of patients 
having a significant reaction.  This included 21 EU, 8 UK and 5 Non-EU 
laboratories.  
The participants were asked if they felt there was sufficient understanding 
regarding allergen component testing amongst: a) Immunology laboratory staff, 
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b) Hospital specialists and c) General Practitioners. The results are summarised 
in figure 3. A key finding was that 78% (n=40) of respondents agreed yes for 
immunology laboratory staff, while 92% (n=47) agreed no for general 
practitioners. There appeared to be a similar perception of need for enhanced 
understanding amongst hospital specialists, where a somewhat similar 42% 
(n=22) were felt to have sufficient understanding and 58% required educational 
input.  
Guidance 
Finally, in order to gauge participants awareness of any national guidelines 
relating to allergen component testing, it transpired that the vast majority (80% 
n=41 out of 51 respondents) were not aware of any such guidance material. 
Those answered yes (n=10) specified various sources including BSACI, WAO 
consensus document, NICE, EAACI and local clinical steering group approach.  
Need for an Allergen component EQA Scheme 
84% (n=43 out of 51 respondents) of respondents would be interested in 
participating in a pilot EQA scheme for allergen component testing.  
Discussion  
This survey provides an overview of the provision of laboratory diagnostic 
services and use of allergen component testing across the UK and Europe. 
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Overall, it confirms there is a wide variation in laboratory practices even within 
the same geographical location.  
In terms of laboratory testing, it appears that a minority of laboratories offer 
more comprehensive testing including the allergen components, whereas 
others only provide the basic specific IgE screening tests.  
The receipt and processing of samples is also highly variable, in that only a 
minority of laboratories appear to have protocols in place to demand-manage 
their workload or ensure appropriate test selection, such as vetting of allergy 
test requests and demand management appeared to be most common in non-
UK laboratories.  
Only a minority (n=3) restrict processing of allergy requests to those that have 
an accompanying completed questionnaire proforma (to ensure that sufficient 
information is available to ensure appropriate testing and useful interpretation). 
The vast majority of laboratories perform testing for all allergens requested by 
the clinician, including mixtures and panels and therefore are totally dependent 
on the clinicians knowledge to ensure appropriate test selection and 
interpretation  
NICE Guidance (DG24) in the UK has recently been published which 
recommends that only experienced specialists should utilise multi-parameter 
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component testing chips like the ISAC, noting that their interpretation is 
complex and the evidence base currently insufficient to make further 
recommendations [10].  Worldwide, a higher proportion of laboratories permit 
component testing requests from primary care professionals (GPs), who may or 
may not have the knowledge and expertise to interpret the results accordingly 
(figure 3). Despite this the laboratories generally reported that they felt 
knowledge of allergen component testing was suboptimal in a large proportion 
of requesters from both primary and secondary care.  
A few laboratories restricted availability of allergen component testing to 
primary care and reserved it exclusively for immunology consultants, allergy 
specialists, and paediatric allergy clinicians. This approach is justified by the need 
for careful clinical history taking skills and clinical judgement in selecting and 
interpreting tests[10].  
The existing repertoire of components for common foods was widely available. 
Most respondents provided of tests for various allergen component categories 
including peanut, egg, venom, and nuts (figure 2).  In addition, some of the non-
UK EU laboratories provided component testing for additional allergens such as 
wheat, fruits, animals, etc. However, fewer laboratories (38% n=17 of 45 
respondents) reported the availability of very specific components for rare 
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allergies e.g. meat alpha-gal component testing for delayed-type anaphylaxis to 
red meat and chimeric anti-cancer drug cetuximab [1].  
Harmonisation of diagnostic approach through agreed algorithms appears to be 
lacking. Although allergen component testing is offered routinely by a significant 
number of laboratories (78% n=45 of 58 respondents), algorithms for selecting 
or interpreting allergen components or allergy testing in general are rarely used, 
and many laboratories do tests as requested and do not modify or gate the 
requests. Consequently, the majority of laboratories reported performing these 
tests regardless of the allergen screen outcome. Interpreting the result of a 
positive component test where the whole extract screen is negative will be a 
challenge, and some might argue that it is a waste of resource to do specific 
testing on screen-negative samples.  
Furthermore, there was little awareness of national guidelines relating to 
component testing amongst the users (80% n = 41 out of 51 respondents lacked 
awareness). A significant proportion of users (74% n=34 of 46 respondents) 
reported the local use of peanut components to stratify clinical risk of patients 
in peanut challenge. However, only 38% reported performing routine allergen 
component testing for peanut positive patients at the time of first testing. This 
in itself may indicate variability in practice.  
Conclusion   
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This survey highlights the increasing use of CRD, accompanied by apparent lack 
of harmonisation of approach and identifies concerns about the need for 
education of test requesters in primary and secondary care settings. It also 
demonstrates geographical differences in terms of testing across the UK and the 
rest of Europe.  
Agreed local or national guideline may help to harmonise laboratory diagnostic 
strategies and illustrates the need for External Quality assessment of the test 
performance of CRD, together with enhanced education on their use. 
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Tables and Figures  
Table 1: No of allergy tests performed per annum in the year 2013 and 2014 
No of allergy tests 
per annum 
No of participants 
2013 2014 
0-10,000 29 (41%) 28 (38%) 
10,000  20,000 11 (15%) 10 (14%) 
20,000  30,000 16 (23%) 14 (19%) 
30,000  50,000 5 (7%) 8 (11%) 
50,000  100,000 5 (7%) 7 (10%) 
100,000+ 5 (7%) 6 (8%) 
Total respondents  n = 71 n = 73 
Table 2: Breakdown of allergy testing requests from various sources 
% of allergy 
tests 
Requesting Source Breakdown 
 
 
Primary care 
 
Secondary care 
 
Other 
 
 
0  20% tests 23 (32%) 12 (17%) 23 (70%*)  
21  40% tests 16 (22%) 12 (17%) 7 (21%*)  
41-60% tests   13 (18%) 22 (31%) 2 (6%*)  
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61-80% tests 9 (13%) 12 (17%) 0  
81-100% tests  11 (15%) 12 (17%) 1(3%*)  
Total 
respondents  
72 70 33  
* Percentage based on total number of respondents (33) for this category only 
instead of all (73) respondents.  
 
 
 
 
 
Figure 1: Breakdown of responses to question 13 - whether participants have 
algorithms for allergy and/or allergen component testing?  
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 Figure 2: Results of question 15 - which allergen components are offered? 
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Figure 3: Results of question 22- Do you feel there is sufficient understanding 
regarding allergen component testing amongst: a) Immunology laboratory 
staff, b) Hospital specialists, and c) General Practitioners?  
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